drugset / Trial / NCT01560143

Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects

NCT01560143

Phase 4 Completed 12 enrolled Manjunath Prakash Pai Pfizer · collab
NaSingle-groupOpen-label

Summary

If tigecycline clearance increases with body size then serum exposure values will be lower in obese class III compared to normal weight subjects because exposure changes inversely with clearance when the dose is fixed without regard to weight.

Timeline

Start
2012-03
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tigecycline Small molecule 100 mg Intravenous

Indications